BNGO - Company ID 0001411690
The table below shows Bionano Genomics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $6.69M | $7.37M | $6.73M | $6.46M | $6.07M | $7.77M |
| Cost of revenue | $3.44M | $4.00M | $3.26M | $3.52M | $14.52M | $5.19M |
| Gross profit | - | - | - | - | - | - |
| R&D | $3.14M | $2.84M | $2.93M | $2.37M | $4.72M | $6.83M |
Bionano Genomics, Inc. reported annual revenue of $28.51M for fiscal year 2025. That is down 7.4% from $30.78M in fiscal 2024. Over the 9 fiscal years shown, annual revenue grew from $9.51M (FY 2017) to $28.51M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $8.01M |
| $9.06M |
| $8.35M |
| $9.03M |
| $9.46M |
| $11.56M |
| Operating income | -$7.90M | -$8.54M | -$7.80M | -$8.46M | -$43.90M | -$17.02M |
| Income tax | $10.00K | $14.00K | $10.00K | $7.00K | $24.00K | $26.00K |
| Net income | -$8.30M | -$8.50M | -$6.86M | -$3.10M | -$44.25M | -$16.22M |
| EPS (diluted) | -$0.76 | -$1.59 | -$1.99 | -$1.15 | -$30.92 | -$14.41 |